Neuromyelitis Optica Spectrum Disorder
Conditions
Keywords
Rhythmic Auditory Stimulation (RAS), Neurology
Brief summary
The purpose of this proof of concept study is to assess the acceptability and safety of MR-C-014 in persons with Neuromyelitis optica spectrum disorder (NMOSD) who have a gait deficit.
Detailed description
This is a single arm, prospective, multi-center feasibility study designed to evaluate the acceptability and safety of MR-C-014. MR-C-014 is an autonomous neurorehabilitation system based on the principles of Rhythmic Auditory Stimulation (RAS) and is designed to operate digitally and autonomously. The core mechanism of RAS is "auditory-motor entrainment." Studies have shown that there is rich connectivity between the auditory and motor systems via multiple cortical and subcortical networks. The MR-C-014 system consists of two foot sensors that measure walking, a locked touchscreen device preloaded with a proprietary software application, a headset, and charging equipment. The electronic components are powered by lithium-ion rechargeable batteries. MR-C-014 is an investigational device.
Interventions
DEVICEMR-C-014
Use of device 3 times per week (for 30 minutes) for 8 weeks - for a total of 24 sessions.
Sponsors
MedRhythms, Inc.
Alexion Pharmaceuticals, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-70 years of age (inclusive). 2. Able to read and/or understand English. 3. Meets revised diagnostic criteria for NMOSD proposed by the International Panel for NMO Diagnosis (IPND) in 2015. 4. Past clinical history of Transverse Myelitis as seen on imaging or as determined by clinical review by the investigator. 5. Demonstrates an observable gait deficit resulting from a diagnosis of NMOSD as determined by the Investigator or medical history review. 6. Currently able to walk at a speed greater or equal to 0.4 m/s, but less than 1.5 m/s, as determined by walking speed during a Timed 25-Foot Walk Test (T25FWT) (cane(s), walking stick(s), crutch(es), wheeled walker, external functional neuromuscular stimulator(s), and ankle foot orthosis allowed). a. Note: if assistive devices are planned to be used during the Intervention Phase walking sessions, they should be used during the Screening, Baseline, and Closing visit gait assessments as well. 7. Has a reciprocal gait pattern. a. Note: a non-reciprocal gait pattern is defined as a 3-point step pattern. Participants must have a 2-point step pattern to qualify. Asymmetry seen in gait is acceptable. 8. Ability and willingness to provide Informed Consent.
Exclusion criteria
1. Unable or unwilling to comply with study protocol. 2. People who become pregnant or are pregnant (due to expected changes in gait patterns). 3. Unable to safely participate in protocol-defined walking sessions of 30-minute duration as determined by the investigator. 4. Significant co-morbid medical or neurological disease or injury, or treatment for such conditions that currently affects, or has potential to affect, participant gait for safety during participation in the study as determined by the investigator. 5. Has an external lower limb prosthetic ("artificial limb"). 6. Initiated physical therapy for lower limb in the past 4 weeks or anticipated to start due to safety concerns (e.g., falls). 7. Requires at least one seated rest during the T25FWT. 8. Initiation, change, or discontinuation of disease-modifying therapy in the past 3 months known to affect gait (e.g., dalfampridine, corticosteroid, medications for spasticity). 9. Recent NMOSD relapse (last 3 months) and/or hospitalization. 10. Severe hearing impairment with or without the use of hearing aids, such that the participant cannot hear the rhythmic music stimulus consistently, as determined by participant and investigator. 11. Treatment with a gait-based investigational intervention within the last 3 months. Enrollment in observational studies is allowed. 12. Vulnerable populations as deemed inappropriate for study by investigator. For this protocol, vulnerable persons are considered to be those who are relatively (or absolutely) incapable of protecting their own interests.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Participant acceptability of MR-C-014 | Intervention period (of up to 8 weeks) | Assesses participant engagement via logged use of MR-C-014 |
| Number of device-related adverse events (AEs) | Weekly for up to 8 weeks | Assesses the safety of MR-C-014 in NMOSD patients with a gait deficit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 6-Minute Walk Test (6MWT) | Baseline and closing (up to 8 weeks) | Assesses distance walked over 6 minutes as a sub-maximal test of aerobic capacity/endurance (distance in meters) |
| Number of walks per week | Weekly for up to 8 weeks | Assesses adherence to recommended frequency of MR-C-014 use. Recommended frequency is 3 walks per week for 8 weeks. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATOREric Klawiter, MD
Massachusetts General Hospital
Outcome results
None listed